The blog is a place to post your thoughts and ideas.

 That got your attention.  It isn’t true—or, at least we don’t know if it’s true.  Antibiotics probably don’t make you fat.

Today CDDEP is excited to release a new video on antibiotic resistance: Unstoppable Superbugs: Closer Than We Think? 

Currently, antibiotic-resistant infections contribute to 99,000 deaths each year in the U.S., and the problem is getting worse. So what can the concerned public do to help? As it turns out, there’s a lot we can do.

A number of Extending the Cure studies have highlighted the changing epidemiology of methicillin-resistant S. aureus (MRSA): first, we noted the emergence of community strains (CA-MRSA) and their move into hospitals, where they added to the existing burden of healthcare-associated strains (HA-MRSA).

The following post by Dr. Daniel J. Morgan, an infectious disease physician at the University of Maryland Medical Center and a staff physician at the Baltimore VA Medical Center, originally appeared on KevinMD.

 The latest Morbidity and Mortality Weekly Report (MMWR) by the US Centers for Disease Control (CDC) addresses the emerging threat of carbapenem-resistant Enterobacteriaceae (CRE). The MMWR, featuring a contribution from CDDEP researchers, reports on the rising prevalence of CREs in US health care facilities and stresses the need for increased surveillance and “a broader, multi-institutional or regional approach” to prevent and control infections. 

The growth of MRSA-related hospitalizations was stagnant between 2005 and 2009; Community-associated infections peak in the summer, likely due to seasonal antibiotic overuse.

The Food and Drug Administration (FDA) is announcing a public hearing to obtain input on the Limited Population Antimicrobial Drug (LPAD) approval pathway – a potential new mechanims to expedite the development of drugs, including biological products, for serious or life-threatening conditions that would address an unmet medical need. The drug’s safety and effectiveness would be studied in a smaller subpopulation of patients with more serious manifestations of a condition.

Proposed LPAD logo

Last week the Pew Charitable Trusts, a signatory on Extending the Cure’s recent Joint Statement on Antibiotic Resistance, hosted a one-day conference titled “A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations.” The event brou

 A  roundup of news on drug resistance and other topics in global health.